Induction of cell differentiation in melanoma cells by inhibitors of IMP dehydrogenase: altered patterns of IMP dehydrogenase expression and activity.
To study the induction of differentiation in human melanoma cells, we treated 12 melanoma cell lines with mycophenolic acid and tiazofurin, inhibitors of IMP dehydrogenase (IMPDH). In all cell lines studied, both agents inhibited cell growth and increased melanin content. However, the degree of growth inhibition did not necessarily correspond to the increase in melanin content. A detailed analysis of the HO and SK-MEL-131 cell lines indicated that mycophenolic acid and tiazofurin caused a time- and dose-dependent increase in the expression of a series of other maturation markers, including formation of dendrite-like structures, tyrosinase activity, and reactivity with the CF21 monoclonal antibody. The growth inhibition and melanogenesis induced by the IMPDH inhibitors was abrogated by the addition of exogenous guanosine. No such effect was observed after treatment of the cells with phorbol 12-myristate 13-acetate or retinoic acid, two other inducers of differentiation in these cells. The mycophenolic acid- and tiazofurin-treated cells also showed an increased level of IMPDH mRNA and protein, perhaps because of compensation for the inhibitor-mediated decrease in IMPDH activity. In contrast, treatment with phorbol 12-myristate 13-acetate or retinoic acid resulted in decreased levels of IMPDH mRNA and protein. The lack of a consistent pattern of IMPDH expression in the cells treated with IMPDH inhibitors and phorbol 12-myristate 13-acetate or retinoic acid suggests that the altered expression of IMPDH is not a general requirement for the induction of cell differentiation in these cells. Our results also suggest that IMPDH inhibitors may provide a useful approach to circumvent the differentiation block in melanoma.
Kiguchi
K
K
Biological and Medical Research Division, Argonne National Laboratory, Illinois 60439-4833.
Collart
F R
FR
Henning-Chubb
C
C
Huberman
E
E
D015415:Biomarkers; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects*; D006151:Guanosine / Q000494:pharmacology; D006801:Humans; D007168:IMP Dehydrogenase / Q000032:analysis / Q000037:antagonists & inhibitors*; D008543:Melanins / Q000096:biosynthesis; D008545:Melanoma / Q000473:pathology*; D014442:Monophenol Monooxygenase / Q000032:analysis; D009173:Mycophenolic Acid / Q000494:pharmacology*; D009363:Neoplasm Proteins / Q000032:analysis / Q000037:antagonists & inhibitors*; D012333:RNA, Messenger / Q000032:analysis; D012334:RNA, Neoplasm / Q000032:analysis; D012254:Ribavirin / Q000031:analogs & derivatives* / Q000494:pharmacology; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D014212:Tretinoin / Q000494:pharmacology; D014407:Tumor Cells, Cultured / Q000187:drug effects / Q000201:enzymology / Q000473:pathology
D015415:Biomarkers; D008543:Melanins; D009363:Neoplasm Proteins; D012333:RNA, Messenger; D012334:RNA, Neoplasm; D006151:Guanosine; D012254:Ribavirin; D014212:Tretinoin; D007168:IMP Dehydrogenase; D014442:Monophenol Monooxygenase; D009173:Mycophenolic Acid; D013755:Tetradecanoylphorbol Acetate; C033706:tiazofurin